CagriSema Dosage Guide
60/100 confidenceComplete guide to CagriSema dosing protocols, administration methods, and safety considerations for research purposes.
Detailed Dosage Information
Phase 3 trial doses
cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection).
Dose escalation
start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose.
Administered as a single injection combining both peptides.
Administration Method
Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026.
Research Backing
REDEFINE Phase 3 program. REDEFINE-1 trial: 22.7% weight loss at 68 weeks. REDEFINE-2 (T2D). Novo Nordisk pipeline. FDA submission accepted, response expected 2026.
Side Effects to Monitor
Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions.
Safety Considerations & Risks
Pre-approval combination therapy — full safety profile not yet established. Carries the same black box warning risk as semaglutide (thyroid C-cell tumors in rodents). Pancreatitis risk. No long-term data beyond 68 weeks. Potential for greater lean mass loss given higher total weight loss.